Promoter methylation of p16, Runx3, DAPK and CHFR genes is frequent in gastric carcinoma

Tumori

Volumn 96, Issue 5, 2010, Pages 726-733

  Hu, Shi Lian ^a   Kong, Xiang Yong ^a   Cheng, Zhao Dong ^a   Sun, Yu Bei ^b   Shen, Gan ^c   Xu, Wei Ping ^d   Wu, Lei ^d   Xu, Xiu Cai ^b   Jiang, Xiao Dong ^a   Huang, Da Bing ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b ANHUI PROVINCIAL HOSPITAL   (China)

^c Cadre's Ward of Anhui PPC Hospital   (China)

^d Anhui Evidence based Medicine Center   (China)

Author keywords

CHFR; DAPK; DNA methylation; Gastric carcinoma; p16; Runx3

Indexed keywords

CHECKPOINT WITH FORKHEAD ASSOCIATED FHA AND RING FINGER PROTEIN; DEATH ASSOCIATED PROTEIN KINASE; MESSENGER RNA; PROTEIN; PROTEIN P16; TRANSCRIPTION FACTOR RUNX3; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER PATIENT; CANCER SIZE; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENDER; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROMOTER REGION; PROTEIN METHYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH BIOPSY; STOMACH CARCINOMA; STOMACH MUCOSA; TUMOR LOCALIZATION;

EID: 78650504704     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089161009600515     Document Type: Article

References (52)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin, 59: 225-249, 2009.
2. Pereira LP, Waisberg J, Andre EA, Zanoto A, Mendes Júnior JP, Soares HP: Detection of Helicobacter pylori in gastric cancer. Arq Gastroenterol, 38: 240-246, 2001.
3. Feinberg AP, Tycko B: The history of cancer epigenetics. Nat Rev Cancer, 4: 143-153, 2004.
4. Issa JP: CpG island methylator phenotype in cancer. Nat Rev Cancer, 4: 988-993, 2004.
5. Jones PA, Laird PW: Cancer epigenetics comes of age. Nat Genet, 21: 163-167, 1999.
6. Robertson KD: DNA methylation and human disease. Nat Rev Genet, 6: 597-610, 2005.
7. Takai D, Jones PA: Comprehensive anxlysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci USA, 99: 3740-3745, 2002.
8. Costello JF, Frühwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomäki P, Lang JC, Schuller DE, Yu L, Bloomfield CD, Caligiuri MA, Yates A, Nishikawa R, Su Huang H, Petrelli NJ, Zhang X, O'Dorisio MS, Held WA, Cavenee WK, Plass C: Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet, 24: 132-138, 2000.
9. Pan Z, Li J, Pan X, Chen S, Wang Z, Li F, Qu S, Shao R: Methylation of the RASSF1A gene promoter in Uigur women with cervical squamous cell carcinoma. Tumori, 95: 76-80, 2009.
10. Esteller M: CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene, 21: 5427-5440, 2002.
11. Geng X, Wang F, Zhang L, Zhang WM: Loss of heterozygosity combined with promoter hypermethylation, the main mechanism of human MutL homolog (hMLH1) gene inactivation in non-small cell lung cancer in a Chinese population. Tumori, 95: 488-494, 2009.
12. Song SH, Jong HS, Choi HH, Kang SH, Ryu MH, Kim NK, Kim WH, Bang YJ: Methylation of specific CpG sites in the promoter region could significantly down-regulate p16(INK4a) expression in gastric adenocarcinoma. Int J Cancer, 87: 236-240, 2000.
13. Katzenellenbogen RA, Baylin SB, Herman JG: Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. Blood, 93: 4347-4353, 1999.
14. Du Y, Carling T, Fang W, Piao Z, Sheu JC, Huang S: Hypermethylation in human cancers of the RIZ1 tumor suppressor gene, amember of a histone/protein methyltransferase superfamily. Cancer Res, 61: 8094-8099, 2001. (Pubitemid 33091596)
15. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature, 366: 704-707, 1993. (Pubitemid 24036021)
16. Cairns P, Mao L, Merlo A, Lee DJ, Schwab D, Eby Y, Tokino K, van der Riet P, Blaugrund JE, Sidransky D: Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science, 265: 415-416, 1994.
17. Scolnick DM, Halazonetis TD: CHFR defines a mitotic stress checkpoint that delays entry into metaphase. Nature, 406: 430-435, 2000.
18. Cortez D, Elledge SJ: Conducting the mitotic symphony. Nature, 406: 354-356, 2000.
19. Levanon D, Negreanu V, Bernstein Y, Bar-Am I, Avivi L, Groner Y: AML1, AML2, and AML3, the humanmembers of the runt domain gene-family: cDNA structure, expression, and chromosomal localization. Genomics, 23: 425-432, 1994.
20. Bae SC, Takahashi EI, Zhang YW, Ogawa E, Shigesada K, Namba Y, Satake M, Ito Y: Cloning, mapping and expression of PEBP2 C, a third gene encoding the mammalian runt domain. Gene, 159: 245-248, 1995.
21. Shim YH, Kang GH, Ro JY: Correlation of p16 hypermethylation with p16 protein loss in sporadic gastric carcinomas. Lab Invest, 80: 689-695, 2000.
22. Schneider-Stock R, Roessner A, Ullrich O: DAP-kinase-protector or enemy in apoptotic cell death. Int J Biochem Cell Biol, 37: 1763-1767, 2005. (Pubitemid 40961661)
23. Ng CS, Zhang J, Wan S, Lee TW, Arifi AA, Mok T, Lo DY, Yim AP: Tumor p16M is a possible marker of advanced stage in non-small cell lung cancer. J Surg Oncol, 79: 101-106, 2002. (Pubitemid 34111935)
24. Mittag F, Kuester D, Vieth M, Peters B, Stolte B, Roessner A, Schneider-Stock R: DAPK promoter methylation is an early event in colorectal carcinogenesis. Cancer Lett, 240: 69-75, 2006.
25. Schildhaus HU, Krockel I, Lippert H, Malfertheiner P, Roessner A, Schneider-Stock R: Promoter hypermethylation of p16INK4a, E-cadherin, O6-MGMT, DAPK and FHIT in adenocarcinomas of the esophagus, esophagogastric junction and proximal stomach. Int J Oncol, 26: 1493-1500, 2005.
26. Herman JG, Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med, 349: 2042-2054, 2003.
27. Tang X, Khuri FR, Lee JJ, Kemp BL, Liu D, Hong WK, Mao L: Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J Natl Cancer Inst, 92: 1511-1516, 2000.
28. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A, 93: 9821-9826, 1996.
29. Kang GH, Lee S, Kim WH, Lee HW, Kim JC, Rhyu MG, Ro JY: Epstein-Barr virus-positive gastric carcinoma demonstrates frequent aberrant methylation of multiple genes and constitutes CpG island methylator phenotype-positive gastric carcinoma. Am J Pathol, 160: 787-794, 2002.
30. Sadikovic B, Rodenhiser DI: Benzopyrene exposure disrupts DNA methylation and growth dynamics in breast cancer cells. Toxicol Appl Pharmacol, 216: 458-468, 2006.
31. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP: CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA, 96: 8681-8686, 1999. (Pubitemid 29354851)
32. Schneider-Stock R, Kuester D, Ullrich O, Mittag F, Habold C, Boltze C, Peters B, Krueger S, Hintze C, Meyer F, Hartig R, Roessner A: Close localization of DAP-kinase positive tumor- associated macrophages and apoptotic colorectal cancer cells. J Pathol, 209: 95-105, 2006.
33. Kang YH, Bae SI, Kim WH: Comprehensive analysis of promoter methylation and altered expression of hMLH1 in gastric cancer cell lines with microsatellite instability. J Cancer Res Clin Oncol, 128: 119-124, 2002.
34. Roa JC, Anabalón L, Roa I, Tapia O, Melo A, Villaseca M, Araya JC: Promoter methylation profile in gastric cancer. Rev Med Chil, 133: 874-880, 2005. (Pubitemid 41602683)
35. Roa SJC, García MP, Melo AA, Tapia EO, Villaseca HM, Araya OJC, Guzmán GP: Gene methylation patterns in digestive tumors. Rev Med Chil, 136: 451-458, 2008.
36. Suzuki H, Itoh F, Toyota M, Kikuchi T, Kakiuchi H, Hinoda Y, Imai K: Distinct methylation pattern and microsatellite instability in sporadic gastric cancer. Int J Cancer, 83: 309-313, 1999. (Pubitemid 29455752)
37. Toyota M, Ahuja N, Suzuki H, Itoh F, Ohe-Toyota M, Imai K, Baylin SB, Issa JP: Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res, 59: 5438-5442, 1999. (Pubitemid 29526452)
38. Shim YH, Kang GH, Ro JY: Correlation of p16 hypermethylation with p16 protein loss in sporadic gastric carcinomas. Lab Invest, 80: 689-695, 2000.
39. Gao N, Chen WC, Cen JN: Relationship between RUNX3 gene expression and its DNA methylation in gastric cancer. Zhonghua Zhong Liu Za Zhi, 30: 361-364, 2008.
40. Kim TY, Lee HJ, Hwang KS, Lee M, Kim JW, Bang YJ, Kang GH: Methylation of RUNX3 in various types of human cancers and premalignant stages of gastric carcinoma. Lab Invest, 84: 479-484, 2004. (Pubitemid 41656475)
41. Gargano G, Calcara D, Corsale S, Agnese V, Intrivici C, Fulfaro F, Pantuso G, Cajozzo M, Morello V, Tomasino RM, Ottini L, Colucci G, Bazan V, Russo A: Aberrant methylation within RUNX3 CpG island associated with the nuclear and mitochondrial microsatellite instability in sporadic gastric cancers. Results of a GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study. Ann Oncol, 18: 103-109, 2007.
42. Sabbioni S, Miotto E, Veronese A, Sattin E, Gramantieri L, Bolondi L, Calin GA, Gafà R, Lanza G, Carli G, Ferrazzi E, Feo C, Liboni A, Gullini S, Negrini M: Multigene methylation analysis of gastrointestinal tumors: TPEF emerges as a frequent tumor-specific aberrantly methylated marker that can be detected in peripheral blood. Mol Diagn, 7: 201-207, 2003.
43. Kim WS, Son HJ, Park JO, Song SY, Park C: Promoter methylation and down-regulation of DAPK is associated with gastric atrophy. Int J Mol Med, 12: 827-830, 2003.
44. Schildhaus HU, Kröckel I, Lippert H, Malfertheiner P, Roessner A, Schneider-Stock R: Promoter hypermethylation of p16INK4a, E-cadherin, O6-MGMT, DAPK and FHIT in adenocarcinomas of the esophagus, esophagogastric junction and proximal stomach. Int J Oncol, 26: 1493-1500, 2005.
45. Waki T, Tamura G, Sato M, Terashima M, Nishizuka S, Motoyama T: Promoter methylation status of DAP-kinase and RUNX3 genes in neoplastic and non-neoplastic gastric epithelia. Cancer Sci, 94: 360-364, 2003.
46. Tang LP, Cho CH, Hui WM, Huang C, Chu KM, Xia HH, Lam SK, Rashid A, Wong BC, Chan AO: An inverse correlation between interleukin-6 and select gene promoter methylation in patients with gastric cancer. Digestion, 74: 85-90, 2006.
47. Chang MS, Uozaki H, Chong JM, Ushiku T, Sakuma K, Ishikawa S, Hino R, Barua RR, Iwasaki Y, Arai K, Fujii H, Nagai H, Fukayama M: CpG island methylation status in gastric carcinoma with and without infection of Epstein-Barr virus. Clin Cancer Res, 12: 2995-3002, 2006.
48. Morioka Y, Hibi K, Sakai M, Koike M, Fujiwara M, Kodera Y, Ito K, Nakao A: Aberrant methylation of the CHFR gene in digestive tract cancer. Anticancer Res, 26: 1791-1795, 2006.
49. Koga Y, Kitajima Y, Miyoshi A, Sato K, Sato S, Miyazaki K: The signifcance of aberrant CHFR methylation for clinical response to microtubule inhibitors in gastric cancer. J Gastroenterol, 41: 133-139, 2006.
50. Gao YJ, Xin Y, Zhang JJ, Zhou J: Mechanism and pathobiologic implications of CHFR promoter methylation in gastric carcinoma. World J Gastroenterol, 14: 5000-5007, 2008.
51. Oki E, Zhao Y, Yoshida R, Masuda T, Ando K, Sugiyama M, Tokunaga E, Morita M, Kakeji Y, Maehara Y: Checkpoint with forkhead-associated and ring finger promoter hypermethylation correlates with microsatellite instability in gastric cancer. World J Gastroenterol, 15: 2520-2525, 2009.
52. Kato K, Iida S, Uetake H, Takagi Y, Yamashita T, Inokuchi M, Yamada H, Kojima K, Sugihara K: Methylated TMS1 and DAPK genes predict prognosis and response to chemotherapy in gastric cancer. Int J Cancer, 122: 603-608, 2008.